Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937233 · ClinicalTrials.gov registry record · Phase 1
Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study
A Phase 1 study of Zika, sponsored by Kathryn Stephenson.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02937233: Completed Phase 1 study of Zika, sponsored by Kathryn Stephenson.
NCT02937233 is a Phase 1 study of Zika that has completed, run by Kathryn Stephenson. The registered enrollment target is 36 participants, below the 1,748-participant average among 3 other Zika trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02937233, a Phase 1 study of Zika, has completed, sponsored by Kathryn Stephenson.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedule.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Zika Virus Purified Inactivated Vaccine
Study Locations (1)
Massachusetts
- Center for Virology and Vaccine Research Clinical Trials Unit, Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-12-08 |
| Est. Completion | 2018-06-04 |
| Phase | Phase 1 |
What the finished NCT02937233 record still lists
NCT02937233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,748-participant average among 3 other Zika trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Zika appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02937233 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02937233 about?
NCT02937233 is a clinical study titled "Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study". This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedu...
What is the current status of trial NCT02937233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-12-08. Estimated completion is 2018-06-04.
What conditions does trial NCT02937233 study?
This clinical trial studies the following conditions: Zika.
What interventions are being tested in trial NCT02937233?
The interventions under investigation include: Placebo (OTHER), Zika Virus Purified Inactivated Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02937233?
This trial is sponsored by Kathryn Stephenson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02937233 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Zika
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
COMPLETED · Phase 1
-
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
RECRUITING
-
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI